Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Applicable field (uses covered by this announcement)
Regenerative medicine, gene therapy, and the manufacture of specified cell-processed products and other materials
Launch date9 October 2026 (scheduled; seminar date)
Relationship between the counterparty and the company
MEDINET Co.,Ltd.2370
Relationship with the Company
Participation as a speaker at an event related to regenerative medicine
Location (as indicated in this announcement)
Pacifico Yokohama
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Official Regenerative Medicine JAPAN 2026 website
| Item | Details |
|---|---|
| Relationship with the Company | Participation as a speaker at an event related to regenerative medicine |
| Launch date | 9 October 2026 (scheduled; seminar date) |
| Applicable area | Regenerative medicine, gene therapy, and the manufacture of specified cell-processed products and other materials |
| Location | Pacifico Yokohama |
| Source | Official Regenerative Medicine JAPAN 2026 website |
Items this document does not state (13)
Names of Products / Services CoveredCounterpartyCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To share information on the role that manufacturers of specified cell-processed products and other materials should play in regenerative medicine technologies provided under the Act on the Safety of Regenerative Medicine.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.